IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 90.76

Change

-0.49 (-0.54)%

Market Cap

N/A

Volume

0.11M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.86 (-0.59%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.36 (-0.52%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.12 (-0.11%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

-0.27 (-0.28%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.17 (-0.75%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.25 (+0.76%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.41 (-0.40%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

-0.40 (-1.29%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.38 (-0.61%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.05 (-0.21%)

USD 6.89M

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.95 % 0.00 %

-0.84 (-0.58%)

USD 1.43B
XHC:CA iShares Global Healthcare.. 99.89 % 0.65 %

-0.37 (-0.58%)

CAD 0.54B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.57% 40% F 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.57% 40% F 81% B-
Trailing 12 Months  
Capital Gain 2.16% 24% F 41% F
Dividend Return 1.45% 88% B+ 23% F
Total Return 3.61% 24% F 32% F
Trailing 5 Years  
Capital Gain 34.02% 57% F 64% D
Dividend Return 8.07% 79% B- 22% F
Total Return 42.10% 57% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.57% 67% D+ 52% F
Dividend Return 6.53% 67% D+ 48% F
Total Return 0.96% 74% C 23% F
Risk Return Profile  
Volatility (Standard Deviation) 13.19% 81% B- 71% C-
Risk Adjusted Return 49.52% 81% B- 63% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike